Axikin Pharmaceuticals, Inc.
Records under this name other than the patents Axikin Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Back to Axikin Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,242,118 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders Term ended Term ended Sep 4, 2022 · USPTO record | Term ended | Term ended Sep 4, 2022 | USPTO record |
| US 7,674,797 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders Lapsed on the fee record Ended Mar 9, 2022 · USPTO record | Lapsed on the fee record | Ended Mar 9, 2022 | USPTO record |
| US 8,658,642 | Arylsulfonamide CCR3 antagonists Lapsed on the fee record Ended Feb 25, 2022 · USPTO record | Lapsed on the fee record | Ended Feb 25, 2022 | USPTO record |
| US 9,637,460 | Isotopically enriched arylsulfonamide CCR3 antagonists Lapsed on the fee record Ended May 2, 2021 · USPTO record | Lapsed on the fee record | Ended May 2, 2021 | USPTO record |
| US 9,540,351 | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors Lapsed on the fee record Ended Jan 10, 2021 · USPTO record | Lapsed on the fee record | Ended Jan 10, 2021 | USPTO record |
| US 9,382,237 | 3,5-diaminopyrazole kinase inhibitors Lapsed on the fee record Ended Jul 5, 2020 · USPTO record | Lapsed on the fee record | Ended Jul 5, 2020 | USPTO record |
| US 9,365,556 | 3,5-diaminopyrazole kinase inhibitors Lapsed on the fee record Ended Jun 14, 2020 · USPTO record | Lapsed on the fee record | Ended Jun 14, 2020 | USPTO record |
| US 9,346,792 | 3,5-diaminopyrazole kinase inhibitors Lapsed on the fee record Ended May 24, 2020 · USPTO record | Lapsed on the fee record | Ended May 24, 2020 | USPTO record |
| US 9,206,186 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders Formerly held Lapsed on the fee record Ended Dec 8, 2019 · USPTO record | Lapsed on the fee record | Ended Dec 8, 2019 | USPTO record |
| US 9,187,425 | 2,5-disubstituted arylsulfonamide CCR3 antagonists Lapsed on the fee record Ended Nov 17, 2019 · USPTO record | Lapsed on the fee record | Ended Nov 17, 2019 | USPTO record |